# A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin

> **NCT01641575** · PHASE1 · TERMINATED · sponsor: **Clovis Oncology, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Solid Tumor
- Non-small-cell Lung Cancer
- Lung Cancer

## Interventions

- **DRUG:** CO-1.01 and Cisplatin

## Key facts

- **NCT ID:** NCT01641575
- **Lead sponsor:** Clovis Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07
- **Primary completion:** 2013-05
- **Final completion:** 2013-06
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Registrational study did not meet endpoint so entire program (including CO-101-011) was terminated.
- **Last updated:** 2014-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01641575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01641575, "A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01641575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*